In their recently published study in Nature, Jenson et al. 1 provide compelling, unexpected evidence that bacterial cGAMP synthase (cGAS) and other cGAS/DncV-like Nucleotidyltransferases (CD-NTase) undergo ubiquitin-like conjugation (ULC) in type-II cyclic-oligonucleotide-based anti-phage signaling systems (CBASS). cGAS conjugation promotes cyclic-nucleotide (CN) formation and thus antiphage defense. Furthermore, the authors also reveal a new class of phage-encoded CBASS inhibitor, T4 Vs.4, a CN-sponge which limits CBASS effector function and promotes phage replication, revealing another weapon in the "arms race" between phages and their bacterial hosts. CN-based signaling is a common element in the antiviral immunity of bacteria, archaea, and metazoans. Bacterial CBASS is essential to antiphage defense and is closely evolutionarily linked to the metazoan antiviral pathway cGAS /STimulator of INterferon Genes (STING). In vertebrates, cGAS has evolved into a receptor for double-stranded DNA, which, upon activation, catalyzes the formation 2'-3'-cGAMP, the ligand for STING, leading to the production of the key vertebrate antiviral cytokine, type-I interferon. This pathway is essential to our own immune defense against numerous bacterial and viral pathogens. As a minimal functional unit, CBASS contains two similar genes: (i) CD-NTase (also termed cGAS in E. coli), which, after an unknown activation mechanism, catalyzes the synthesis of CN second messengers and (ii) Cap, which, like metazoan STING, senses CN and carries out signaling and effector functions, including cell death programs. However, the type-II CBASS operon also encodes two ancillary genes, Cap2 and Cap3 2 (Fig. 1), that surprisingly contain domains resembling eukaryotic ubiquitin-activating (E1, Cap2),-conjugating (E2, Cap2) and-deconjugating (JAB/JAMM, Cap3) enzymes. Little is known about protein conjugation in bacteria, and, although it had previously been shown that the enzymatic activities of Cap2 and Cap3 promote antiphage defense, 3 the potential targets of these de/conjugating enzymes and their downstream molecular mechanisms remained completely unclear. To address these questions, Jenson and colleagues utilized a straightforward but effective approach: E.coli MG1655, which lacks CBASS, was used for the expression of diverse type-II CBASS systems 3 and modifications thereof throughout the manuscript (Fig. 1). In initial experiments, FLAG-Cap2 was incorporated into E. coli TW11681 CBASS to identify interactors via immunoprecipitation, and putative loss-of-function (LOF) Cap2 and Cap3 mutants 3